Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the percentage of participants achieving an American College of Rheumatology 20% improvement response (ACR20) at Week 12.
Epistemonikos ID: 4d378c91f24818e7f6f7b4601d3ed9a6a596bc2d
First added on: Mar 23, 2022